Tag Archives: Gilead

Europe: More Direct-Acting Antivirals, More Controversy

The storms raging across Europe—and beyond—over the pricing of new hepatitis C treatments have been intensified by the European Union’s approval last week of the latest directly-acting antiviral, Bristol-Myers Squibb’s Daklinza (daclatasvir). Just two months after the European Medicines Agency gave a positive opinion on the drug, the formal authorization was delivered for use in […]
Posted in Europe, Global, Guest Blog, Op-Ed, pricing, Regulatory | Also tagged , , , , , | Leave a comment

The Market Will Demand a Cheaper Alternative to Sovaldi

A new report from Frost & Sullivan forecasts “robust demand” for HCV antivirals, with several strong competitors “maneuvering aggressively” to narrow the market gap by introducing a treatment that can outdo Gilead’s Sovaldi.
Posted in healthcare, pricing, Strategy | Also tagged , , | Leave a comment

Paying for the Future of Medicine

Is the hallmark of innovation higher drug prices? The three leading justifications for sticker-shocking drug prices in the US, from the biopharma perspective, are: 1) it costs a lot to bring a drug to market;* 2) drugs – even very expensive ones – are cheaper in the long run since they prevent complications, hospitalizations and […]
Posted in Biotech, FDA, healthcare, leadership, Manufacturing, Market Access, pricing, R&D, Regulatory, Technology | Also tagged , , , , , | 1 Comment

Sovaldi “Biggest Selling Drug” by 2020

Gilead’s hepatitis C treatment Sovaldi will top the list of biggest selling drugs in 2020, according to UK market intelligence company, Evaluate. “Given its history-making launch, it is no surprise that [Sovaldi] is forecast to become the biggest drug in 2020; the big question will be how long this drug can hang onto the top spot,” […]
Posted in Europe, Gene therapy, Global, Sales, Strategy | Also tagged , , , , , , | Leave a comment

High Price of Gilead's Sovaldi Could Deter Early Hep C Treatment

Gilead Silences has cleaned up on their new $1,000 Hepatitis C pill Sovaldi (84,000 per treatment), hauling in a record-breaking $2.3 billion in its first full quarter on the market. The previous record (also a Hepatitis C drug Incivek from Vertex) came in with $1.56 billion, according to EP Vantage. And Sovaldi may well go […]
Posted in healthcare, pricing | Also tagged , | 1 Comment
  • Categories

  • Meta